Cipla Q1: consolidated PAT down 39% YoY to ₹786 Cr on US Revlimid/Lanreotide loss

Cipla opened FY27 with a soft print as consolidated net profit fell 39.2% year-on-year to ₹785.55 Cr (from ₹1,291.61 Cr in Q1 FY26) on near-flat revenue of ₹7,119.28 Cr (+2.3% YoY). The headline QoQ optics look strong — PAT up 44.8% and revenue up 8.8% — but that is off a weak Q4 FY26 base (₹542.51 Cr PAT, dented by an impairment) and is not the story; the year-on-year comparison is, and it is a clear step down against a very strong year-ago quarter. The damage is entirely at the margin line. EBITDA margin compressed to ~16.8% from 25.6% a year ago, and net margin fell to 11.0% from 17.9%, as the high-margin US portfolio rolled off — the loss of generic Revlimid revenue and the absence of Lanreotide supplies, exactly the headwinds brokerages had flagged. Cost of materials and purchases held broadly flat but employee cost (₹1,497 Cr, +14% YoY) and depreciation (₹304 Cr, +20% YoY) rose, so the operating deleverage on a flat topline drove the profit fall. There was no exceptional item this quarter, so the drop is clean and operational rather than accounting-driven — unlike FY26, which carried a ₹275.91 Cr labour-code charge. The result missed the street: Nuvama had modelled revenue +5.9% and PAT −30.7% YoY, and Motilal Oswal expected US sales down ~28%; Cipla came in weaker on both topline (+2.3%) and bottom line (−39%). Against management's own FY27 guidance — EBITDA margin of 18.5–20% with an explicitly H2-weighted, new-launch-driven ramp, a $1bn US run-rate by FY27-end (excluding Lanreotide), and market-beating double-digit India growth — Q1's ~16.8% margin runs below the band but is consistent with the guided back-ended shape; the guidance is intact but now visibly H2-dependent. Concurrent corporate developments this quarter were largely governance/housekeeping (90th AGM, appointment of B S R & Co. as statutory auditor, one USFDA observation at a subsidiary, an ESG rating revised down to 64) and did not move the numbers. Standalone PAT of ₹862.16 Cr exceeded consolidated, reflecting a ₹34.33 Cr aggregate net loss across the overseas/subsidiary base.